why does semaglutide cause muscle loss matters: the effects of medically induced weight on skeletal muscle Do GLP-1 medications really cause

The benefits of semaglutide aren't confined to mere weight loss but extend to improving crucial health markers related to conditions such as heart disease, stroke, and type 2 diabetes, rendering it a comprehensive approach to sustained health betterment

Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

Education is critical because semaglutide is given either as a weekly injection or as a daily pill

Its important to follow the prescribed schedule closely to maintain stable drug levels in the body

However, as they are not FDA approved and have not been vetted in long-term trials there is no way to guarantee their safety, efficacy or potency. Now, as drug manufacturers successfully push the FDA to remove semaglutide and tirzepatide from the shortage list, access to compounded versions may soon disappear